ALK and non-small cell lung carcinoma: Crizotinib is a small molecule inhibitor of multiple tyrosine kinases, most notably ALK and ROS1. In a study of 50 patients with NSCLC and ROS1 rearrangement, treatment with crizotinib resulted in a 72% response rate and median PFS of 19.2 months [25].